Cellectar Biosciences (CLRB) said Tuesday it presented a poster at the American Society of Hematology conference in San Diego providing highlights of the company’s phase 2 dose escalation clinical study of CLR 131 to assess safety and tolerability of the compound in patients with relapsed or refractory multiple myeloma.
Results demonstrated that all eight evaluable patients of the ten enrolled achieved a minimum of stable disease. The poster also reported a mean of approximately three months of progression-free survival in cohort 1 and four months in cohort 2.
Significantly, four of eight patients experienced a greater than 50% reduction in serum free light chains, which are a key efficacy indicator for multiple myeloma.
Seven of eight evaluable patients achieved a reduction in either serum or urine M protein, which also are key efficacy indicators for multiple myeloma.
The primary endpoint for this study is to determine the safety and tolerability of CLR 131 in a heavily pre-treated patient population.